Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients

Mineral and Electrolyte Metabolism

Volumn 23, Issue 3-6, 1997, Pages 170-173

  Jungers, Paul ^a   Chauveau, Phillipe ^a   Bandin, Olivia ^a   Chadefaux, Bernadette ^a   Aupetit, Joëlle ^a   Labrunie, Mathilde ^a   Descamps Latscha, Béatrice ^a   Kamoun, Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Accelerated atherosclerosis; Chronic renal failure; Homocysteine; Hyperhomocysteinemia; Occlusive arterial disease

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; BRAIN INFARCTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERHOMOCYSTEINEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ARTERIOSCLEROSIS; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL DIALYSIS; UREMIA;

EID: 0030720051     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Malinow MR: Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994;236:603-617.
2. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration; in Scriver CR, Beaudet AL, Sly WS, Valle DS (eds): The Metabolic and Molecular Bases of inherited Disease, ed 7. New York, McGraw-Hill, 1995, vol 2, pp 1279-1327.
3. Kang S, Wong PWK, Cook HY, Norusis M, Messer JV: Protein-bound homocyst(e)ine: A posible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-1486.
4. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
5. Stampfer MJ, Malinow MR, Willett WC: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
6. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 1990;81:51-60.
7. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaeffer EJ, Rosenberg IH: Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332:286-291.
8. Wilcken DEL, Gupta VJ: Sulphur-containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301-307.
9. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 1992;18:196-198.
10. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43(suppl 41):S72-S77.
11. Hultberg B, Anderson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-234.
12. Jungers P, Chauveau P, Ceballos I, Bardet J, Parvy P, Hannedouche T, Kamoun P: Plasma free aminoacid alterations from early to end-stage chronic renal failure. J Nephrol 1994;7:48-54.
13. Wilcken DEL, Gupta VJ, Reddy SG: Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 1980;58:427-430.
14. Kang SS, Wong PWK, Bidani A, Milanez S: Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis. Clin Sci 1983;65:335-336.
15. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121-125.
16. Wilcken DEL, Gupta VJ, Betts AK: Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci 1981;61:743-749.
17. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Druëke TB, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994;9:1103-1108.
18. Ibels LS, Stesart JH, Mahony JF, Neale FC, Sheil AGR: Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients: A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis. Q J Med 1977; 46:197-214.
19. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993;21:77-80.
20. Harpel PC, Chang VT, Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-10197.
21. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
22. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996;22:106-109.
23. Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Anderson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993;40:236-240.
24. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
25. Janssen MJ, Van Guldener C, De Jong GMT, Van den Berg M, Stehouver CDA, Donker AJM: Folie acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996;22:110-114.
26. Swainson C, Winney R: Do dialysis patients need extra folate? Lancet 1983;i:239.
27. Westhuyzen J, Matherson K, Tracey R, Fleming SJ: Effect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 1993;40:96-99.
28. Brattstrom L, Israelsson B, Jeppson H, Hultberg B: Folic acid, an innocuous means of reducing plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-221.
29. Stampfer MJ, Malinow MR: Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995;332:328-329.